Tag: genetics

23andMe, a company once valued at $6 billion in 2021, has experienced a steep decline, now trading as a penny stock and facing the risk of NASDAQ delisting. Founded in 2006 by Anne Wojcicki, the company revolutionized direct-to-consumer genetic testing, lowering the cost of its kits and securing FDA approval. However, slowed sales, one-time-use nature…